Effect of Intravaginal Prasterone on Symptoms of VVA in Women Under Treatment With an Aromatase Inhibitor for Breast Cancer
Status:
Withdrawn
Trial end date:
2019-12-05
Target enrollment:
Participant gender:
Summary
The purpose of this study is to confirm the efficacy of intravaginal prasterone (DHEA) on
moderate to severe (MS) and most bothersome symptoms (MBS) of vulvovaginal atrophy (VVA) due
to natural, surgical or treatment-induced menopause, in women with breast cancer who are
under treatment with an aromatase inhibitor.